Cerebral Trypanosoma cruzi Reactivation in HIV/AIDS: MRI Findings, Brain Chagoma, and the Diagnostic Importance of Kinetoplasts

How Chagas Disease Can Reactivate in the Central Nervous System and Mimic Cerebral Toxoplasmosis in Immunocompromised Patients

Edited by ScholarGen MediAI | Medical Imaging & Clinical AI Research

Executive Answer

Cerebral reactivation of Trypanosoma cruzi is an uncommon but potentially life-threatening neurological complication of chronic Chagas disease in patients with profound immunosuppression, particularly those with advanced HIV infection. It may present as a large intracranial mass, brain abscess, or meningoencephalitis and can closely resemble cerebral toxoplasmosis or primary central nervous system lymphoma on MRI. A particularly important diagnostic clue is the identification of intracellular organisms containing prominent kinetoplasts in tissue specimens. In the appropriate epidemiological and clinical setting, recognizing this finding can prevent a potentially serious diagnostic delay.

Why This Case Matters

A large cerebral mass in a patient with newly diagnosed AIDS immediately raises concern for opportunistic infection and HIV-associated malignancy.

In clinical practice, cerebral toxoplasmosis is frequently considered when an immunocompromised patient presents with fever, headache, altered mental status, and intracranial mass lesions. Primary central nervous system lymphoma is another important consideration.

However, an uncommon diagnosis must remain in the differential when the patient's epidemiological background suggests exposure to an endemic pathogen.

This case illustrates an important diagnostic principle:

A cerebral mass in an immunocompromised patient should not automatically be attributed to toxoplasmosis simply because the patient has advanced HIV infection and positive Toxoplasma IgG antibodies.

Reactivation of chronic Trypanosoma cruzi infection can produce substantial cerebral lesions and neurological deterioration. Its recognition requires integration of clinical history, MRI findings, tissue morphology, and molecular identification.

1. Clinical Presentation

A 31-year-old man recently diagnosed with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) presented to the emergency department with:

Headache
Confusion
Gait instability
Fever

He had immigrated to the United States from El Salvador six years earlier.

Physical examination demonstrated a temperature of 38.9°C and ataxia.

Laboratory evaluation revealed:

Laboratory parameter	Reported result
CD4+ T-cell count	60 cells/mm³
HIV viral load	409,000 copies/mL
Toxoplasma gondii IgG	Positive
Toxoplasma gondii IgM	Negative

The CD4+ count of 60 cells/mm³ indicates profound cellular immunosuppression.

The combination of fever, neurological symptoms, and severe immunodeficiency required urgent investigation for central nervous system opportunistic infection.

The patient's history of residence in El Salvador was also clinically relevant because T. cruzi infection is endemic in parts of Central and South America.

Importantly, the six-year interval since immigration does not exclude chronic Chagas disease. The infection can persist for years or decades before becoming clinically apparent.

2. Brain MRI: A Large Intracranial Lesion

Brain MRI demonstrated a large lesion involving the corpus callosum and extending into the subcortical white matter of the right parietal and occipital lobes.

The reported lesion dimensions were:

8 × 7 × 6 cm

The examination included axial T2-weighted and postcontrast T1-weighted images.

Figure 1. Axial T2-Weighted Brain MRI

Radiologic interpretation

The axial T2-weighted image demonstrates extensive abnormal signal involving the posterior cerebral hemispheric white matter, with extension across the corpus callosum.

The lesion is large and heterogeneous in appearance.

Its involvement of the corpus callosum and adjacent subcortical white matter is an important anatomical feature because it indicates a substantial infiltrative or inflammatory process rather than a small, isolated cortical abnormality.

In an immunocompromised patient, this distribution should prompt consideration of several important diagnostic categories:

Opportunistic cerebral infection
Primary central nervous system lymphoma
Other infiltrative neoplastic processes
Granulomatous or inflammatory disease

The anatomical extent is particularly important. A large lesion involving the corpus callosum should not be interpreted without considering both infectious and neoplastic causes.

Clinical significance

The MRI appearance establishes the presence of a major intracranial abnormality but cannot independently identify the responsible organism.

This distinction is essential when evaluating cerebral lesions in patients with advanced HIV infection.

Figure 2. Axial Postcontrast T1-Weighted Brain MRI

Radiologic interpretation

The postcontrast T1-weighted image demonstrates abnormal peripheral and heterogeneous enhancement associated with the extensive cerebral lesion.

The enhancement pattern supports the presence of an active pathological process involving the cerebral parenchyma.

In this clinical setting, the principal diagnostic challenge is distinguishing an opportunistic infection from an HIV-associated intracranial neoplasm.

A ring-enhancing or peripherally enhancing cerebral lesion is not specific to a single disease.

The differential diagnosis includes:

Cerebral toxoplasmosis
Trypanosoma cruzi reactivation with cerebral chagoma
Primary central nervous system lymphoma
Tuberculous granuloma or tuberculoma
Fungal infection
Pyogenic brain abscess

The MRI findings should therefore be interpreted alongside epidemiological history, immune status, laboratory results, and tissue examination.

3. Why Toxoplasmosis Was an Important Diagnostic Consideration

Cerebral toxoplasmosis is a major opportunistic infection in patients with advanced HIV/AIDS.

The positive Toxoplasma gondii IgG result indicates previous exposure to the organism and makes reactivation an important consideration in a severely immunocompromised patient.

However, IgG positivity does not establish that the current brain lesion is caused by active toxoplasmosis.

Similarly, negative IgM does not exclude reactivation of a previously acquired infection.

The imaging overlap between cerebral toxoplasmosis and cerebral Chagas disease creates a significant diagnostic challenge.

Both conditions can produce intracranial mass lesions with contrast enhancement.

Consequently, imaging alone may not provide a definitive distinction.

In this case, the decisive diagnostic evidence came from examination of the brain aspirate and subsequent molecular identification of the organism.

4. The Decisive Finding: Kinetoplasts Within Intracellular Organisms

Figure 3. Cytologic Examination of Brain Aspirate Demonstrating Intracellular Organisms With Prominent Kinetoplasts

Cytopathologic interpretation

Cytological examination of the brain aspirate demonstrated intracellular organisms containing prominent kinetoplasts within macrophages and astrocytes.

The kinetoplast is a specialized DNA-containing structure associated with the mitochondrion of kinetoplastid protozoa.

It contains a highly organized network of mitochondrial DNA and represents an important morphological feature in the identification of organisms belonging to the order Kinetoplastida.

In the appropriate morphological context, the presence of intracellular organisms with prominent kinetoplasts strongly supports infection by a kinetoplastid parasite.

In this patient, partial protozoal 28S ribosomal RNA sequencing identified the organism as Trypanosoma cruzi.

This molecular result established the diagnosis.

Why the Kinetoplast Is So Important

The kinetoplast is more than a microscopic structural detail.

It provides a critical diagnostic clue when evaluating intracellular parasitic organisms in tissue specimens.

In cerebral Chagas disease, T. cruzi can be present in its intracellular amastigote form within host tissues.

Recognition of these organisms is particularly important in immunocompromised patients because the clinical and radiological manifestations may be nonspecific.

The combination of:

Intracellular organisms
Prominent kinetoplasts
Appropriate cytological morphology
Molecular identification of T. cruzi

provides a much stronger diagnostic foundation than MRI appearance alone.

5. Understanding Cerebral Chagas Disease

Chagas disease, also known as American trypanosomiasis, is caused by the protozoan parasite Trypanosoma cruzi.

The infection is endemic in several regions of Mexico, Central America, and South America.

Transmission

The principal vector is the infected triatomine bug, commonly called the kissing bug.

Transmission occurs primarily when infected insect feces contaminate the bite wound or mucosal surfaces.

Other recognized routes include:

Congenital transmission
Contaminated blood transfusion
Organ transplantation
Oral transmission through contaminated food or drink

An important epidemiological point is that infection does not necessarily become symptomatic immediately after exposure.

Chronic infection can remain clinically silent for many years.

The Two Major Clinical Phases

Acute Chagas disease

The acute phase usually occurs shortly after infection.

Possible manifestations include fever, fatigue, malaise, and local inflammatory changes at the site of parasite entry.

Severe cases may involve myocarditis or neurological complications.

Chronic Chagas disease

After the acute phase, many infected individuals enter a prolonged chronic stage.

A substantial proportion remain asymptomatic for years or decades.

However, chronic infection can eventually produce clinically significant cardiac disease, including cardiomyopathy and arrhythmias. Gastrointestinal complications such as megaesophagus and megacolon may also occur.

In patients with profound immunosuppression, the clinical behavior of the infection can change dramatically.

6. Why HIV/AIDS Can Trigger Cerebral Reactivation

The immune system plays a critical role in controlling chronic T. cruzi infection.

In advanced HIV infection, progressive depletion of CD4+ T lymphocytes compromises cellular immune responses.

This loss of immune control can permit previously contained parasites to replicate more actively.

The consequences may include:

Increased parasitemia
Meningoencephalitis
Cerebral inflammatory lesions
Brain abscess-like lesions, also called chagomas

The risk is particularly important in patients with very low CD4+ counts.

The present case demonstrates this relationship clearly.

The patient's CD4+ count was only 60 cells/mm³, providing a clinical context in which reactivation of chronic infection becomes a serious consideration.

Why the Epidemiological History Matters

The patient's origin in El Salvador was not merely demographic information.

It was a diagnostic clue.

When a patient from a Chagas-endemic region develops neurological symptoms in the setting of advanced HIV infection, clinicians should consider chronic T. cruzi infection and possible reactivation.

The disease may become clinically apparent long after the patient has left the endemic region.

This is particularly relevant to healthcare systems in the United States, where clinicians increasingly encounter patients with infections acquired outside the country.

7. Differential Diagnosis of Cerebral Mass Lesions in AIDS

The differential diagnosis of intracranial mass lesions in patients with AIDS requires a structured approach.

Condition	Important diagnostic considerations
Cerebral toxoplasmosis	Common opportunistic infection; may produce multiple enhancing lesions
Cerebral Chagas disease	Consider in patients with epidemiological exposure to T. cruzi; may involve white matter and produce large lesions
Primary CNS lymphoma	Important HIV-associated neoplasm; may involve deep structures and the corpus callosum
Tuberculoma	Consider with relevant epidemiological and clinical risk factors
Fungal infection	May produce mass-like lesions, abscesses, or granulomatous abnormalities
Pyogenic abscess	Requires assessment for infectious source and characteristic diffusion findings

Cerebral Toxoplasmosis Versus Chagas Reactivation

The distinction between these two infections deserves particular attention.

Both may produce enhancing cerebral lesions in patients with advanced HIV infection.

Although some published observations describe differences in lesion distribution, there is considerable imaging overlap.

Therefore, lesion location, size, and enhancement pattern should guide the differential diagnosis rather than determine the final diagnosis.

Tissue examination and direct identification of the parasite may be essential when imaging and clinical information remain inconclusive.

Primary CNS Lymphoma

Primary central nervous system lymphoma is another important consideration in patients with advanced HIV/AIDS.

The corpus callosum is a recognized anatomical location for infiltrative CNS neoplasms.

This makes the presence of a large callosal lesion particularly challenging.

However, the identification of intracellular kinetoplast-bearing organisms and molecular confirmation of T. cruzi establish an infectious etiology in this case.

8. Diagnostic Approach: From MRI to Molecular Confirmation

A practical diagnostic framework for suspected cerebral Chagas disease can be summarized as follows.

Step 1. Identify the clinical risk

Assess:

HIV status
CD4+ T-cell count
History of residence in endemic regions
Previous Chagas disease diagnosis
Neurological symptoms

Step 2. Perform appropriate neuroimaging

Brain MRI is particularly useful for evaluating lesion distribution, parenchymal involvement, enhancement, and associated abnormalities.

CT may also be useful in the initial assessment of patients presenting to the emergency department.

Step 3. Establish the differential diagnosis

Consider toxoplasmosis, lymphoma, tuberculosis, fungal infection, pyogenic abscess, and cerebral Chagas disease when epidemiologically appropriate.

Step 4. Obtain organism-specific diagnostic evidence

Depending on the clinical situation, investigations may include:

Examination of blood smears
Cerebrospinal fluid examination
Molecular testing
Tissue cytology or histopathology

Step 5. Confirm the diagnosis

Identification of the parasite or its products in an appropriate clinical specimen provides definitive evidence of infection or reactivation.

In the present case, the diagnosis was established through cytological identification of intracellular organisms and partial 28S ribosomal RNA sequencing.

9. Treatment and Clinical Outcome

The patient received benznidazole followed by initiation of antiretroviral therapy.

After two weeks of treatment, clinical improvement was observed in both mental status and gait.

This response is clinically important because it demonstrates improvement following treatment directed against the identified parasitic infection and management of the underlying HIV disease.

Benznidazole and nifurtimox are established antiparasitic agents used in the treatment of Chagas disease.

However, treatment decisions in patients with advanced HIV infection and central nervous system involvement require specialist management.

Antiretroviral therapy is also essential for addressing the underlying immunodeficiency.

The NIH HIV opportunistic infection guidelines recommend treatment of acute or reactivated T. cruzi infection and initiation or optimization of antiretroviral therapy in people with HIV and concomitant Chagas disease.

The precise treatment regimen and monitoring strategy must be individualized by the treating clinical team.

Importantly, the two-week clinical improvement reported in this case should not be interpreted as proof of complete parasitological eradication or long-term cure.

10. Radiology AI Perspective: Can Artificial Intelligence Help Recognize Cerebral Chagas Disease?

This case also raises an important question for the development of clinical artificial intelligence in neuroimaging.

Can AI-assisted brain MRI interpretation help identify unusual opportunistic infections in immunocompromised patients?

Potentially, yes—but the role must be defined carefully.

A. Automated Lesion Detection

Deep learning-based medical imaging systems can be developed to identify abnormal intracranial regions and assist with lesion localization.

For a large cerebral lesion involving the corpus callosum and adjacent white matter, automated segmentation could potentially help quantify:

Lesion volume
Anatomical distribution
Relationship to adjacent structures
Changes on serial MRI examinations

These measurements may assist clinical assessment and follow-up.

However, lesion detection is not equivalent to pathogen identification.

B. Differential Diagnosis Support

A multimodal clinical AI system could theoretically integrate:

MRI findings
CD4+ T-cell count
HIV viral load
Epidemiological history
Serological results
Pathology findings

This approach could help identify unusual diagnostic possibilities that might otherwise receive less attention.

For example, a patient with advanced HIV infection, a large white matter lesion, and a history of residence in El Salvador represents a clinical context in which Chagas disease deserves consideration.

Nevertheless, no AI diagnostic performance or validated prediction capability has been established by this case.

C. Pathology Image Analysis

Digital pathology and computer vision may provide additional opportunities.

An AI-assisted microscopy system could potentially be developed to identify intracellular structures suspicious for kinetoplast-bearing organisms.

Such a system would require carefully annotated training data and independent validation.

Because these infections are uncommon, obtaining sufficiently representative datasets would be a major challenge.

D. AI Limitations

Several limitations must be considered:

Rare-disease data scarcity: Cerebral Chagas disease is uncommon, making large, representative training datasets difficult to obtain.
Imaging overlap: Toxoplasmosis, lymphoma, and other infections can produce similar MRI appearances.
Domain shift: Models trained at one institution may not generalize to different scanners, acquisition protocols, or patient populations.
False-positive alerts: Excessive alerts may increase radiologist workload.
False-negative results: A negative AI assessment must never be used to exclude an unusual opportunistic infection.
Clinical context: MRI alone cannot establish the presence of T. cruzi.

The appropriate role of AI is to support lesion detection, anatomical assessment, and diagnostic prioritization—not to replace microbiological or molecular confirmation.

11. Healthcare Workflow Implications

This case illustrates how a rare infection can expose weaknesses in conventional diagnostic workflows.

A radiologist may identify a large intracranial lesion, but the final diagnosis depends on collaboration among several clinical disciplines.

An effective workflow may involve:

Emergency Department → Brain MRI → Neuroradiology Interpretation → Infectious Disease Consultation → Neurosurgical/Tissue Evaluation → Cytopathology → Molecular Diagnostics → Targeted Treatment

The most important opportunity is timely integration of information.

If epidemiological history is not communicated to the radiology and infectious disease teams, an unusual diagnosis may receive insufficient consideration.

Similarly, pathology findings must be interpreted in the context of the clinical presentation.

For healthcare organizations, this case supports the value of coordinated diagnostic workflows rather than isolated interpretation by individual departments.

12. Diagnostic Pitfalls and Practical Radiology Pearls

Pitfall 1: Anchoring on toxoplasmosis

Positive Toxoplasma IgG in a patient with AIDS does not prove that a cerebral mass is toxoplasmosis.

Pitfall 2: Ignoring geographical history

Previous residence in Central or South America may provide important information about chronic parasitic infections.

Pitfall 3: Assuming that MRI can identify the pathogen

Enhancement patterns are not sufficiently specific to establish cerebral Chagas disease.

Pitfall 4: Overlooking the corpus callosum

Callosal involvement should broaden the differential diagnosis to include both infiltrative neoplasms and infectious processes.

Pitfall 5: Underestimating the value of cytology

Identification of intracellular kinetoplast-bearing organisms may provide a decisive diagnostic clue.

Pitfall 6: Confusing clinical improvement with microbiological cure

Neurological improvement after treatment does not independently establish complete parasite clearance.

Practical Radiology Pearls

Consider cerebral Chagas disease in immunocompromised patients with relevant epidemiological exposure.
Large white matter lesions can occur with T. cruzi reactivation.
Cerebral toxoplasmosis and Chagas disease may have overlapping MRI appearances.
Intracellular organisms containing kinetoplasts are an important morphological clue.
Molecular identification can establish the organism responsible for an otherwise nonspecific cerebral lesion.
Clinical history, imaging, cytology, and molecular testing should be interpreted together.

13. Frequently Asked Questions

1. What causes cerebral Chagas disease?

Cerebral Chagas disease results from reactivation of chronic Trypanosoma cruzi infection in patients with impaired immune function. Advanced HIV infection is an important risk factor.

2. What is the characteristic MRI finding of cerebral Chagas disease?

MRI may demonstrate enhancing cerebral lesions involving subcortical white matter. Large lesions and mass-like abnormalities can occur, although imaging findings are not specific.

3. Can cerebral Chagas disease mimic toxoplasmosis?

Yes. Both infections may produce enhancing intracranial lesions in patients with advanced HIV/AIDS. Clinical history and direct organism identification are important for differentiation.

4. What is a kinetoplast?

A kinetoplast is a specialized mitochondrial DNA-containing structure found in kinetoplastid protozoa. Its presence within an intracellular organism can provide an important diagnostic clue.

5. Which insect transmits Trypanosoma cruzi?

The principal vector is the triatomine bug, also known as the kissing bug.

6. Can Chagas disease remain asymptomatic for many years?

Yes. Chronic infection can persist for years or decades without obvious clinical manifestations before complications develop.

7. How is cerebral Chagas disease confirmed?

Confirmation requires identification of the parasite or its products in an appropriate specimen, using microscopy, cytology, histopathology, or molecular methods as clinically appropriate.

8. What is the role of benznidazole?

Benznidazole is an antiparasitic medication used to treat T. cruzi infection, including reactivated disease. Treatment requires clinical supervision.

9. Can artificial intelligence diagnose cerebral Chagas disease from MRI alone?

No validated MRI-only AI approach can establish this diagnosis. AI may assist with lesion detection and differential diagnosis, but organism-specific confirmation remains essential.

14. Clinical Knowledge Check

Question 1

A 31-year-old man with advanced HIV infection presents with fever, confusion, and gait instability. MRI demonstrates a large cerebral lesion involving the corpus callosum and adjacent white matter. Which additional diagnosis should be considered in a patient originally from El Salvador?

A. Neurocysticercosis
B. Cerebral Chagas disease
C. Multiple sclerosis
D. Acute ischemic stroke

Question 2

Cytological examination of a brain aspirate demonstrates intracellular organisms containing prominent kinetoplasts. Which organism is most strongly suggested?

A. Toxoplasma gondii
B. Cryptococcus neoformans
C. Trypanosoma cruzi
D. Mycobacterium tuberculosis

Question 3

Which insect is the principal vector responsible for transmitting Trypanosoma cruzi?

A. Anopheles mosquito
B. Triatomine bug
C. Ixodes tick
D. Phlebotomine sand fly

Question 4

Which laboratory finding in this patient indicates profound cellular immunosuppression?

A. Positive Toxoplasma IgG
B. Negative Toxoplasma IgM
C. CD4+ count of 60 cells/mm³
D. HIV viral load of 409,000 copies/mL

Question 5

What is the most important limitation of MRI in diagnosing cerebral Chagas disease?

A. MRI cannot demonstrate cerebral white matter abnormalities.
B. MRI cannot evaluate intracranial mass lesions.
C. MRI findings overlap with other infections and neoplasms and cannot independently identify the pathogen.
D. MRI is unnecessary in immunocompromised patients.

Answers: 1-B, 2-C, 3-B, 4-C, 5-C.

15. Key Takeaways

Cerebral reactivation of Trypanosoma cruzi is a rare but important complication of advanced immunosuppression.

This case provides several clinically relevant lessons:

A history of residence in an endemic region remains important even years after immigration.
Severe CD4+ T-cell depletion can permit reactivation of chronic parasitic infection.
Cerebral Chagas disease can present as a large intracranial mass involving white matter.
MRI findings may overlap with cerebral toxoplasmosis and primary CNS lymphoma.
Intracellular organisms containing prominent kinetoplasts provide an important diagnostic clue.
Molecular identification of T. cruzi can establish the definitive etiology.
Benznidazole treatment and antiretroviral therapy are important components of management.
AI can potentially support imaging and pathology workflows but cannot replace organism-specific confirmation.

The central diagnostic lesson is that an unusual infection should not be excluded simply because a more common opportunistic disease appears plausible.

In patients with advanced HIV infection, accurate diagnosis depends on integrating epidemiological history, neuroimaging, cytopathology, and molecular evidence.

References

[1] E. H. Clark, L. A. Messenger, J. D. Whitman, and C. Bern, “Chagas disease in immunocompromised patients,” Clinical Microbiology Reviews, vol. 37, no. 2, Art. no. e00099-23, Mar. 2024, doi: 10.1128/cmr.00099-23.

[2] N. Elkheir, J. Carter, C. Dominic, P. Lok, T. Fisayo, M. Michelen, B. De Barros, J. Wilson Goldsmith, M. Butler, A. Price, A. Mehotra, L. Nabarro, N. Ahmed, P. L. Chiodini, and D. A. J. Moore, “The epidemiology and clinical features of HIV and Trypanosoma cruzi (Chagas disease) co-infection: A systematic review and individual patient data analysis,” PLoS Neglected Tropical Diseases, vol. 20, no. 1, Art. no. e0012808, Jan. 2026, doi: 10.1371/journal.pntd.0012808.

[3] M. Kaushal, S. Shabani, E. J. Cochran, H. Samra, and N. T. Zwagerman, “Cerebral trypanosomiasis in an immunocompromised patient: Case report and review of the literature,” World Neurosurgery, vol. 129, pp. 225–231, Sep. 2019, doi: 10.1016/j.wneu.2019.05.260.

[4] A. Fica, M. Salinas, M. I. Jercic, J. Dabanch, A. Soto, S. Quintanilla, and C. Flores, “Chagas disease affecting the central nervous system in a patient with AIDS demonstrated by quantitative molecular methods,” Revista Chilena de Infectología, vol. 34, no. 1, pp. 69–76, Feb. 2017, doi: 10.4067/S0716-10182017000100011.

[5] G. A. Di Lorenzo, M. A. Pagano, A. L. Taratuto, M. L. Garau, F. J. Meli, and M. D. Pomsztein, “Chagasic granulomatous encephalitis in immunosuppressed patients: Computed tomography and magnetic resonance imaging findings,” Journal of Neuroimaging, vol. 6, no. 2, pp. 94–97, Apr. 1996, doi: 10.1111/jon19966294.

[6] D. Gluckstein, F. Ciferri, and J. Ruskin, “Chagas' disease: Another cause of cerebral mass in the acquired immunodeficiency syndrome,” The American Journal of Medicine, vol. 92, no. 4, pp. 429–432, Apr. 1992, doi: 10.1016/0002-9343(92)90275-G.

[7] E. de Oliveira Santos, J. dos Reis Canela, H. C. G. Monção, and M. J. G. Roque, “Reactivation of Chagas' disease leading to the diagnosis of acquired immunodeficiency syndrome,” The Brazilian Journal of Infectious Diseases, vol. 6, no. 6, pp. 317–321, Dec. 2002, doi: 10.1590/S1413-86702002000600009.

[8] E. Molina Solano, M. Mora Díaz, S. Montoya Madriz, M. Lizano Calvo, and L. Retana Moreira, “Concomitant diagnosis of Trypanosoma cruzi and HIV in a patient with neurologic manifestations: A case report,” The Brazilian Journal of Infectious Diseases, vol. 28, no. 6, Art. no. 104478, Nov.–Dec. 2024, doi: 10.1016/j.bjid.2024.104478.

[9] National Institutes of Health, “Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Chagas Disease,” updated Jun. 14, 2023, reviewed Mar. 16, 2026. [Online]. Available: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/chagas-disease

[10] Centers for Disease Control and Prevention, “How Chagas Disease Spreads,” updated Feb. 4, 2026. [Online]. Available: https://www.cdc.gov/chagas/spreads/index.html

Medical Disclaimer

This article is intended for medical education and professional discussion. It does not replace individualized clinical assessment, specialist consultation, or institutional diagnostic and treatment protocols.